As of 2026-09-18, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 11.3x | 8.8x |
| Forward P/E multiples | 11.7x - 15.8x | 14.2x |
| Fair Price | (22.04) - (21.47) | (21.77) |
| Upside | -703.8% - -688.3% | -696.3% |
| Date | EV/EBITDA |